{
    "Trade/Device Name(s)": [
        "Access Folate Assay"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K223590",
    "Predicate Device Reference 510(k) Number(s)": [
        "K060774",
        "K111952"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CGN"
    ],
    "Summary Letter Date": "August 23, 2023",
    "Summary Letter Received Date": "July 27, 2023",
    "Submission Date": "November 30, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.1295"
    ],
    "Regulation Name(s)": [
        "Folic Acid Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Folic acid"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Lithium heparin plasma",
        "Red blood cells"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Access Immunoassay Systems",
        "DxI 9000 Access Immunoassay Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Paramagnetic particle",
        "Chemiluminescent immunoassay",
        "Competitive binding immunoassay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Beckman Coulter Access Folate Assay for quantitative measurement of folic acid in serum, plasma, and red blood cells using chemiluminescent immunoassay",
    "Indications for Use Summary": "Quantitative determination of folic acid levels in human serum, lithium heparin plasma, and red blood cells to assist in the diagnosis and treatment of megaloblastic anemia and assessment of folate status",
    "fda_folder": "Clinical Chemistry"
}